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ing by ElAbstract Background: Although partial splenic embolization (PSE) has been widely used for
treatment of leucocytopaenia and thrombocytopaenia in cirrhosis, only few studies evaluate both
beneﬁts and complications of it.
Objective: To evaluate outcome of partial splenic embolization beneﬁts on both platelet and leuco-
cytes counts and its complications in treatment of cirrhotic patients.
Patients andmethods: Cirrhotic patients with hypersplenism-induced thrombo-cytopenia underwent
partial splenic embolization (PSE). From All patients complete history and full clinical examination
were taken and subjected toLaboratory investigations. After PSEwas performed, the precise extent of
embolization was calculated on CT examinations 2 weeks after PSE. Prophylactic antibiotics was
given for 5 days after PSE.All patients were then followed up at the outpatient clinic. Peripheral blood
cell parameters includingwhite blood cell (WBC), platelet (PLT) and red blood cell (RBC) countswere
monitored prior to PSE, on the 3rd, 14th, 30th day after PSE, and subsequently at 3-month intervals
during the 2-year follow-up period. The complications associated with PSE were appropriately
recorded. All patients underwent abdominal CT scanning before and 2 weeks after PSE.534149.
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36 S.A. Elmonem et al.Results: Twenty three patients were included in this study. 13 (57%) males and 10 (43%) females
with mean age 42.37 years. PSE was successfully performed in all 23 patients. Post-embolization
syndrome 91.3% (21/23) was the most frequent side effect. Other minor complications as puncture
site hematoma occurred to one patient at site of femoral artery. Severe complications occurred in
eight patients (34.8%). two patients had a large amount of pleural effusion and ascites. One
patients developed bacterial peritonitis and died of septicaemia. One patient complicated by sple-
nic abscess. One patient had recurrent thrombo-cytopenia and treated by PSE. Portal vein throm-
bosis was found in one patient. One patient presented with huge splenomegaly and improved after
splenectomy. Post-PSE, the platelets and leucocytes counts showed increase in the number. Best
results obtained with larger splenic infarction area but in the expense of more major complica-
tions.
Statistical analysis: Blood parameters were compared using paired t test. P< 0.05 means signif-
icant differences.
Conclusion: PSE is a useful treatment in patients with hypersplenism caused by cirrhosis. PSE is
safe in advanced disease patients, not suitable for splenectomy, with good long-term effect on the
hematological parameters and a reduction in bleeding episodes from esophageal varices.
 2011 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
All rights reserved.1. Introduction
Partial splenic embolization (PSE) for hyper-splenism has been
reported to achieve a prolonged improvement in blood cell
counts (1–4). In recent times, PSE has been widely applied to
improve thrombo-cytopenia in cirrhotic patients prior to the
administration of pegylated interferon and ribavirin for treat-
ing hepatitis C virus infection (5–7). Partial splenic emboliza-
tion (PSE), which has been thought to be an effective
alternative to splenectomy (8,9) because of its milder injury
and fewer complications, has been widely used for the treat-
ment of leuko-cytopenia and thrombo-cytopenia caused by hy-
per-splenism since the report of Maddison in 1973 (10). The
procedure helps occlude the arterial supply of the spleen more
peripherally, which results in ischemic necrosis of much of the
functional spleen followed by a decrease in splenic size and hy-
per-splenism. It also allows preservation of adequate splenic
tissue and thereby avoids the risk of overwhelming post-sple-
nectomy infection (11). In patients with chronic liver disease,
the procedure reduces immunologic induction of thrombo-
cytopenia (12). Undoubtedly the spleno-megaly in cirrhosis is
due mainly to reticulo-endothelial hyperplesia, and Hemody-
namic studies have shown that the consequent increase in the
splenic component of portal blood ﬂow doesn’t contribute to
increased portal pressure (13).
Although surgical splenectomy constitutes an effective
treatment of hyper-splenism, it has major drawbacks, it jeopar-
dizes future shunt options by removal of splenic vein and for
liver transplant candidates, and it makes the deﬁnitive surgery
more difﬁcult. In addition, spleen-ectomy carries signiﬁcant
post operative morbidity and long-term risk of over-whelming
infection (14).
However, partial splenic embolization method occasionally
has been associated with serious complications, such as splenic
abscess and septicemia (15). The study was conducted based
on the hypotheses that partial splenic embolization has the
advantage of being a non-operative intervention, that it is safe
and effective in the management of secondary hyper-splenism,
and that it is equivalent or even superior to other options espe-
cially spleen-ectomy in the management of hyper-splenism in
patients with chronic liver disease.2. Methods
From April 2006 to May 2009, 23 patients with hyper-splenism
caused by cirrhosis underwent partial splenic embolization
PSE. The diagnosis of hypersplenism was determined by clin-
ical examination, laboratory data, ultra-sonography and com-
puted tomography examinations. The enrolling criteria for this
study were: patients with splenomegaly and thrombo-cytope-
nia (platelet counts 660 · 109/L1) and/or leuko-cytopenia
(leukocyte counts 63.0 · 109/L1). The excluding criteria were:
(1) patients who had spontaneous bacterial peritonitis; (2)
patients with hepatocellular carcinoma. Potent supporting
therapies were performed for patients having severe peritoneal
effusion before PSE in order to decrease the amount of ascites.
Patients meeting the above criteria were randomly assigned
into this study.
All patients gave informed consent before their participa-
tion in the study. From All patients complete history and full
clinical examination were taken and subjected to Laboratory
investigations including: complete blood count, liver function
tests, kidney function tests, HBsAg and HCV-antibody.
Under strict aseptic conditions, PSE was performed as fol-
low: a 5.0 French catheter (Cobra head catheter) was inserted
into the femoral artery by the modiﬁed Seldinger method. Ce-
liac angiography and selective splenic arterial angiography
were routinely performed to observe the distribution of splenic
arteries and collateral circulation routes. Then, the tip of the
catheter was placed as distal as possible at the hilus of the
spleen (to avoid embolization of pancreatic and short gastric
arteries), and embolization was performed using injections of
a gelatin sponge (Gelfoam cube, Upjohn, Kalamazoo, USA),
(1–2 mm), suspended in an antibiotic solution (1 g cefazolin-
containing solution) and contrast medium. The extent of
embolization was set at 50–70%. To achieve this, embolization
was performed progressively by means of repeated injections
of gelfoam particles under angio-graphy control. Immediate
angio-graphy was done after each injection and the extent of
embolization was calculated, roughly, by ﬁnding the percentage
of the ablated splenic parenchyma area shown by post-embo-
lization angiography against the total splenic parenchyma
area given by pre-embolization angiography. When a 50–70%
Fig. 1 (A and B) Huge splenomegally after partial splenic embolization ‘intra-operative splenectomy’.
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zation ended. Finally, the precise extent of embolization was
calculated on CT examinations 2 weeks after PSE. Post-PSE
supportive care included appropriate hydro-electrolytic infu-
sion, systemic prophylaxis with antibiotics, using amoxicillin-
clavulanate (3 g/day) and oﬂoxacin (400 mg/day) for at least
5 days after PSE, and adapted analgesic treatment using para-
cetamol or morphine.
All patients stayed in hospital after PSE until the post-
embolization syndrome or any other severe complications
had disappeared, and were then followed up at the outpatient
clinic. Peripheral blood cell parameters including white blood
cell (WBC), platelet (PLT) and red blood cell (RBC) counts
were monitored prior to PSE, on the 3rd, 14th, 30th day after
PSE, and subsequently at 3-month intervals during the 2-year
follow-up period. The complications associated with PSE were
appropriately recorded.
All patients underwent abdominal CT scanning (CT, HiS-
peed CT/I; GE Medical Systems, Milwaukee, WI, USA) be-
fore and 2 weeks after PSE. After that, CT scanning
performed every 6 months. Whole and residual splenic vol-
umes before and after PSE were evaluated based on the CT
examination taken 2 weeks after PSE.
Statistical analysis platelet count and leucocytic count pre
and post-PSE were compared using paired t test. P< 0.05
means signiﬁcant differences.
3. Results
Twenty three patients (Figs. 1–4) were included in this study.
The characteristics of the patients are shown in Table 1. The
Child-Pugh classiﬁcations of these 23 patients were grade A
in 11 (48%), grade B in 9 (39%) and grade C in 3 (13%) pa-
tients. PSE was successfully performed in all 23 patients.
Post-embolization syndrome was the most frequent side
effect in this study consisting of abdominal pain, fever and
mild nausea and vomiting. The incidence of post-embolization
syndrome was 91.3% (21/23). The degree of pain remarkably
differed. The duration of pain was 2–19 days (mean: 7.82 ±
4.13 days). The duration of fever and vomiting also were vari-ables. The duration of fever was 1–17 days (mean: 8.43 ±
5.49 days). The duration of vomiting was 1–6 days (mean:
2.72 ± 1.89 days). Other minor complications as puncture site
hematoma occurred to one patient at sit of femoral artery.
Severe complications occurred in eight patients (34.8%) as
listed in Table 2. Two patients had a large amount of pleural
effusion and ascites, which caused dyspnea, and resolved by
thoraco-centesis and peritoneo-centesis. 0ne patients devel-
oped bacterial peritonitis after 12 days of PSE, the patient
admitted to Intensive Care Unit but died of septicaemia
22 days after PSE in spite of intensive antibiotic therapy and
supportive care. One patient with persistent fever (more than
38.0 C) for 17 days after PSE was found to have splenic ab-
scess by abdominal CT scans. The abscess was drained with
a catheter and absorbed after 5 weeks. One patient had recur-
rent thrombo-cytopenia and treated by PSE but with bigger
splenic infarction area. Portal vein thrombosis was found in
one patient on CT. One patient presented with huge spleno-
megaly (Fig. 5A&B) 7 months after PSE which causes heavi-
ness in the abdomen, dyspnea and dyspepsia. She improved
after splenectomy.
Within the ﬁrst 2 weeks post-PSE, the platelets showed in-
crease in the number more than twice the pre-PSE levels. After
that, it started to decrease gradually up to the end of the
2 years follow up. Although the decreases in platelet number
during the follow up period, the mean number of platelet at
the end of 2 years follow up was (80.410).
Of the 23 patients, four were not available by the end of 2-
year follow-upbecause of, one died of hepatocellular carci-
noma, one died of septicaemia (a PSE-related complication)
22 days after PSE and two missed follow up. The remaining
19 patients underwent the follow-up over 2 years. There is sig-
niﬁcant statistical difference in improvement of thrombo-cyto-
penia and leuco-penia between pre-PSE and post-PSE (Table
3). P-value was less than 0.05.
4. Discussion
Hypersplenism is a well-known complication of portal hyper-
tension in cirrhosis, which can result in thrombocytopaenia
Fig. 2 (A and B) Pre-embolization arteriography of the spleen. (C and D) Post-embolization of the enlarged spleen reveals decreased
vascularity of the spleen. (E) Contrast enhanced CT scan of the abdomen two weeks after splenic embolization reveals partial infarction of
the spleen (appears as non-enhanced hypodense areas).
38 S.A. Elmonem et al.and/or leucocytopaenia. In some patients, severe peripheral
cytopaenia may prevent treatments, such as interferon therapy(16), antineoplastic chemotherapy (17), and major surgery
(18), and spontaneous bleeding events may also occur. Surgical
Fig. 3 (A) Pre-embolization arteriography of the markedly enlarged spleen, (B) during embolization. (C) Post-embolization reveals
decreased vascularity and size of the spleen due to ablated splenic parenchymal area. (D) Contrast enhanced CT scan of the abdomen two
weeks after splenic embolization reveals splenic non-enhanced hypodense areas of infarction.
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destruction, but the morbidity of severe complications after
spleen-ectomy still ranges from 9.6% to 26.6%, including lap-
aroscopic and open spleen-ectomy (19–21). In addition, sple-
nectomy is often associated with an increased long-term risk
of septic events (19–21). PSE has been proposed as an effective
alternative to splenectomy (8,9,22). Several studies have re-
ported the feasibility of this procedure, claiming favourable re-
sults in cirrhotic patients –– a signiﬁcant increase in both
platelet and leucocytes counts (23,3,18,24,1).
Our study showed signiﬁcant improvement in both platelet
and leucocytes counts. They reached the peak level on the third
day and in the second week after PSE, respectively, and then
gradually fell during the follow-up period. The reason of the
decrease is perhaps attributable to splenic regeneration after
PSE, because we observed changes in splenic volumes after
PSE. Although this fell, both platelet and leucocytes counts
continued much higher than the pre-PSE level. Only one pa-
tient showed signiﬁcant thrombo-cytopenia because of lowinfarction area and treated by PSE with infarction area more
than 50%. Also, we noted that the increase in infracted area
of the spleen lead to more increase in both platelet and leuco-
cytes counts but with increase in the rate and severity of the
complications. Therefore, we believed that, to gain long-term
efﬁcacy of PSE to alleviate hypersplenism, at least 50% splenic
infarction should be achieved.
Post-embolization syndrome was the most frequent side ef-
fect (85.5%), which was usually tolerable to the patients them-
selves and was easily controlled via conservative therapy (18).
In this study, the incidence of post-embolization syndrome
exhibited a close relationship with the splenic infarction rate.
Transient pleural effusion and/or ascites, as well as small
left-sided atelectasis also occurred frequently. Though all these
side effects could be controlled with conservative therapy and
a longer hospital stay was required.
Although the signiﬁcant number of complication of PSE,
but still less than that of surgical splenectomy especially in crit-
ical patient. PSE has been demonstrated to be safe, especially
Fig. 4 (A and B) Pre-embolization arteriography of the enlarged spleen. (C) During embolization and (D) post-embolization reveals
decreased vascularity and size and the spleen due to ablated splenic parenchymal area.
40 S.A. Elmonem et al.with regard to the advanced diseases among the patients, with
a high risk of complications related to the underlying cytope-
nias and hepatic insufﬁciency. Major studies, including a larg-Table 1 Characteristics of the patients.
Characteristics Patients undergoing PSE
Age (years) Mean ± SD 42.37 ± 7.21
Total number 23
Sex
Male 13 (57%)
Female 10 (43%)
Platelet (·109 L1) Mean ± SD 41.3 ± 13.0
WBC (·109 L1) 2.31 ± 0.47
HCV antibody All +ve
HBsAg 11 (48%)
Child’s classiﬁcation
A 11 (48%)
B 9 (39%)
C 3 (13%)est one with data on 40 patients (18), did not focus on the
evaluation of severe complications after PSE. Nevertheless, a
number of reports have been published (15,25–29) concerning
such severe complications as portal vein thrombosis (26,29),
severe bacterial peritonitis (15), and splenic abscess resulting
in death in certain cases (26,15). However, few studies (30)Table 2 Complications.
Major complication No. %
Signiﬁcant pleural eﬀusion or ascites 2 8.7
Bacterial peritonitis 1 4.3
Splenic abscess 1 4.3
thrombocytopenia 1 4.3
Portal vein thrombosis 1 4.3
Huge spleen 1 4.3
PSE-related death 1 4.3
Total 8 34.8
Mean ± SD.
Fig. 5 (A and B) Pre-embolization arteriography of the markedly enlarged spleen. (C) Post-embolization reveals decreased vascularity
and size of the spleen.
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infarction rate, revealing that severe complications occurred
more frequently in patients with more than 70% splenic infarc-
tion. In our study, we tried to keep the splenic infarction rateTable 3 Follow-up results both platelet and leucocytes counts
(·109 L1).
Time Platelets Leucocytes
Mean
(·109 L1)
SD P-value Mean
(·109 L1)
SD P-value
Pre-PSE 41.3 ±13.0 2.31 ±0.47
Post-PSE
2 weeks 124.29 ±23.91 <0.05 8.26 ±1.54 <0.05
1 month 115.76 ±18.36 <0.05 6.53 ±1.74 <0.05
6 months 103.58 ±14.83 <0.05 5.21 ±1.39 <0.05
1 year 94.13 ±12.89 <0.05 4.62 ±1.13 <0.05
2 years 80.41 ±15.17 <0.05 4.27 ±0.82 <0.05
SD: standard deviation.to be between 50%-70%, to reach the best long-term results
and to avoid sever complications. Such complications were
found in 8 out of 23 patients (34.8%). According to these re-
sults, we believe that the splenic infarction rate should be
strictly limited to not more than 70% in order to reduce severe
complications. In the PSE procedure, quantitative control of
the splenic infarction rate remains challenging. The reduced
rate of splenic arterial blood ﬂow was usually used as an indi-
cator of splenic embolized rate, but the result largely depended
on the operator’s experience. In this study, our intention was
to ablate 50–70% of the splenic parenchyma, but such a result
could not be achieved well. Thus, in order to achieve more
accurate splenic infarction rate and avoid excess embolization,
we believed that a graded PSE could be more reasonable and
feasible.
5. Conclusion
In conclusion, PSE is a useful treatment in patients with hyper-
splenism caused by cirrhosis. PSE is safe in advanced diseased
patients, not suitable for spleen-ectomy, with good long-term
42 S.A. Elmonem et al.effect on the hematological parameters and a reduction in
bleeding episodes from esophageal varices. Even in advanced
cases of hepatic insufﬁciency there is good clinical palliation
and improvement in the general status.
Our study aimed to evaluate the effectiveness of PSE in
treatment of thrombo-cytopenia and leuco-cytopenia due to
hyper-splenis in patient with liver cirrhosis.
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